School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Int J Mol Sci. 2024 Aug 22;25(16):9110. doi: 10.3390/ijms25169110.
Steroid-resistant asthma (SRA), resisting glucocorticoids such as dexamethasone (DEX), is a bottleneck in the treatment of asthma. It is characterized by a predominantly neutrophilic inflammatory subtype and is prone to developing into severe refractory asthma and fatal asthma. Currently, there is a lack of universally effective treatments for SRA. Moreover, since cold stimulation does increase the risk of asthma development and exacerbate asthma symptoms, the treatment of cold-stimulated SRA (CSRA) will face greater challenges. To find effective new methods to ameliorate CSRA, this study established a CSRA mouse model of allergic airway inflammation mimicking human asthma for the first time and evaluated the alleviating effects of 80% ethanol extract of mountain-cultivated ginseng (MCG) based on multi-omics analysis. The results indicate that cold stimulation indeed exacerbated the SRA-related symptoms in mice; the DEX individual treatment did not show a satisfactory effect; while the combination treatment of DEX and MCG could dose-dependently significantly enhance the lung function; reduce neutrophil aggregation; decrease the levels of LPS, IFN-γ, IL-1β, CXCL8, and IL-17; increase the level of IL-10; alleviate the inflammatory infiltration; and decrease the mucus secretion and the expression of MUC5AC. Moreover, the combination of DEX and high-dose (200 mg/kg) MCG could significantly increase the levels of tight junction proteins (TJs), regulate the disordered intestinal flora, increase the content of short-chain fatty acids (SCFAs), and regulate the abnormal gene profile and metabolic profile. Multi-omics integrated analysis showed that 7 gut microbes, 34 genes, 6 metabolites, and the involved 15 metabolic/signaling pathways were closely related to the pharmacological effects of combination therapy. In conclusion, integrated multi-omics profiling highlighted the benefits of MCG for CSRA mice by modulating the interactions of microbiota, genes, and metabolites. MCG shows great potential as a functional food in the adjuvant treatment of CSRA.
类固醇抵抗性哮喘(SRA)对糖皮质激素如地塞米松(DEX)抵抗,是哮喘治疗的一个瓶颈。它的特点是主要为中性粒细胞炎症亚型,容易发展成严重的难治性哮喘和致命性哮喘。目前,SRA 缺乏普遍有效的治疗方法。此外,由于寒冷刺激确实会增加哮喘发展的风险并加重哮喘症状,因此治疗冷刺激性 SRA(CSRA)将面临更大的挑战。为了寻找改善 CSRA 的有效新方法,本研究首次建立了一种模拟人类哮喘的 CSRA 小鼠模型的过敏性气道炎症,并基于多组学分析评估了山参 80%乙醇提取物(MCG)的缓解作用。结果表明,寒冷刺激确实加重了小鼠的 SRA 相关症状;DEX 单一治疗效果并不理想;而 DEX 和 MCG 的联合治疗可以剂量依赖性地显著增强肺功能;减少中性粒细胞聚集;降低 LPS、IFN-γ、IL-1β、CXCL8 和 IL-17 的水平;增加 IL-10 的水平;缓解炎症浸润;减少黏液分泌和 MUC5AC 的表达。此外,DEX 和高剂量(200mg/kg)MCG 的联合治疗可以显著增加紧密连接蛋白(TJs)的水平,调节紊乱的肠道菌群,增加短链脂肪酸(SCFAs)的含量,并调节异常的基因谱和代谢谱。多组学综合分析表明,7 种肠道微生物、34 个基因、6 种代谢物以及涉及的 15 种代谢/信号通路与联合治疗的药理作用密切相关。总之,整合多组学分析通过调节微生物群、基因和代谢物的相互作用,突出了 MCG 对 CSRA 小鼠的益处。MCG 作为 CSRA 辅助治疗的功能性食品具有巨大潜力。